Document Type : Original Article
Authors
1
Professor of Physiology, Department of Physiology, Faculty of Medicine, Diabetes Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2
Assistant Professor of Physiology, Department of Physiology, Faculty of Medicine, Cellular and Molecular Research Center, Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
3
Associate Professor of Medical Histology, Department of Anatomical Sciences, Faculty of Medicine, Cellular and Molecular Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4
Professor of Pharmaceutics, Department of Pharmaceutics, Faculty of Pharmacy, Nanotechnology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
5
Professor of Physiology, Department of Physiology, Faculty of Medicine, Physiology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Abstract
Background: Type 2 diabetes mellitus (T2DM) has several complications such as hyperlipidemia and hepatotoxicity. Myricitrin has an antidiabetic action along with low bioavailability. So, the aim of the present study was to investigate hypolipidemic and hepatoprotective effects of myricitrin and solid lipid nanoparticle (SLN) containing myricitrin on the T2DM mouse model induced by Streptozotocin-nicotinamide (STZ-NA).
Methods: In this experimental study, 90 Naval Medical Research Institute (NMRI) adult male mice were divided into 9 groups (n=10 per group): control, vehicle, diabetic, diabetic + myricitrin, or SLN containing myricitrin 1, 3, and 10 mg/kg groups. The cold homogenization method was used to prepare SLN containing myricitrin. The diabetic model was induced by one injection of STZ-NA (65-120 mg/kg) with a 15-min interval. Animals' treatment was done for 4 weeks. At the end of the experiment, plasma samples were taken for experimental assessments.
Results: Plasma level of triglyceride (TG), low-density lipoprotein (LDL-C), very-low-density lipoprotein (VLDL), aspartate aminotransferase (AST), and alanine aminotransferase (ALT) increased and high-density lipoprotein cholesterol (HDL-C) decreased in diabetic mice compared to the control group (p <0.05). Administration of myricitrin or SLN containing myricitrin decreased plasma levels of TG, LDL-C, VLDL, AST, and ALT and increased HDL-C in the treated diabetic groups compared to the untreated groups (p <0.05).
Conclusion: According to the results, myricitrin and SLN containing myricitrin showed hypolipidemic and hepatoprotective effects in T2DM mice. Also, SLN containing myricitrin was more potent than myricitrin especially in a low dose of administration.
Keywords